PubMed Health⌕ Search

Biomedical subjects

Y M el-Sayed

Publications and source records attributed to Y M el-Sayed.

At least 19 recordsLinked to original sources

Predictive performance of four pharmacokinetic methods for calculating digoxin dosage.

An evaluation was made of the performance of the Sheiner, Koup, Dobbs and Paulson methods for predicting total body clearance of digoxin in 59 patients with and without congestive heart failure (CHF). The predicted clearances were then used to predict the steady-state serum concentrations of digoxin. Actual serum concentrations were measured at steady state following single oral daily doses of digoxin for at least 1 month. Predictive performance was determined for each method by calculating the mean prediction error (ME) and the mean squared prediction error (MSE). Ninety-five per cent confidence intervals and correlation coefficients were also calculated. The prediction bias and precision of the methods were compared statistically by calculating the 95% confidence intervals of the delta ME and delta MSE. For patients with CHF, the Sheiner method was the least biased and the most precise for predicting observed serum levels. For patients without CHF, no significant difference between the Sheiner and Koup methods, and between the Dobbs and Paulson methods were seen, although the former two methods were less biased and more precise than the latter two. The Sheiner method was used as the basis for evaluating the performance of the three other methods in predicting digoxin clearance from patients with and without CHF. This revealed that the Koup, Dobbs and Paulson methods tended to overpredict clearances in patients with CHF; on the other hand, for patients without CHF, the Koup method was the least biased and the most precise of the three methods.

Adult↗

Comparative bioavailability of two tablet formulations of metoclopramide hydrochloride.

This investigation was carried out to evaluate the bioavailability of a new tablet formulation of metoclopramide hydrochloride (10 mg), Metosil relative to a recognized product, Plasil BP. The two brands were found to be similar in assay and content uniformity and both met the BP requirements of disintegration time. The bioavailability was carried out on 18 healthy male volunteers who received a single dose (2 x 10 mg) of the test (T) and the recognized (R) products in a randomized balanced 2-way crossover design. After dosing, serial blood samples were collected for a period of 8 hours. Plasma harvested from blood was analyzed for metoclopramide by a sensitive and validated high-performance liquid chromatographic assay. The maximum plasma concentration (Cmax), area under the plasma concentration curve up to the last measurable concentration (AUC0-t), and to infinity (AUC0-00) were analyzed statistically under the assumption of a multiplicative model. The time to maximum concentration (Tmax) was analyzed assuming an additive model. The parametric confidence intervals (90%) of the mean values of the pharmacokinetic characteristics (AUC0-t AUC0-00 and Cmax) for T:R ratio were in each case well within the bioequivalence acceptable range of 0.8-1.25. The test formulation was found bioequivalent to the reference formulation by the Schuirmann's 2 one-sided t-tests and by Wilcoxon-Mann-Whitney 2 one-sided tests procedure. Therefore, the two formulations were considered to be bioequivalent.

Administration, Oral↗

Comparative bioavailability of two tablet formulations of ibuprofen.

This investigation was carried out to evaluate the bioavailability of a new tablet formulation of ibuprofen (600 mg), Profinal, relative to reference product, Brufen (600 mg) tablets. The 2 brands were found to be similar in assay, weight variation and dissolution as stipulated by the USP XXII, as well as the disintegration time, as specified by the BP 1988. The bioavailability was carried out on 18 healthy male volunteers who received a single dose (600 mg) of the test (T) and the reference (R) products in the fasting state, in a randomized balanced 2-way crossover design. After dosing, serial blood samples were collected for a period of 12 hours. Plasma harvested from blood was analyzed for ibuprofen by a sensitive and validated high-performance liquid chromatographic assay. The maximum plasma concentration (Cmax), area under the plasma concentration-curve up to the last measurable concentration (AUC0-t), and to infinity (AUC0-infinity) were analyzed statistically under the assumption of a multiplicative model. The time to maximum concentration (Tmax) was analyzed assuming an additive model. The parametric confidence intervals (90%) of the mean values of the pharmacokinetic characteristics (AUC0-t, AUC0-infinity and Cmax) for T:R ratio were in each case, well within the bioequivalence acceptable range of 80-125%. The test formulation was found bioequivalent to the reference formulation by the Schuirmann's 2 1-sided t-tests and by Wilcoxon-Mann-Whitney 2 1-sided tests procedure. Therefore, the 2 formulations were considered to be bioequivalent.

Administration, Oral↗

The effect of colestipol and cholestyramine on ibuprofen bioavailability in man.

The purpose of this study was to determine whether a concomitant single oral dose of one of the anion exchange resins colestipol hydrochloride (10 g) or cholestyramine (8 g) administered with ibuprofen (400 mg) would alter the bioavailability of this non-steroidal anti-inflammatory agent. The study was performed according to a randomized three-way crossover design in six healthy male volunteers. After dosing, serial blood samples were collected for a period of 10 h. Plasma harvested from blood was analysed for ibuprofen by a sensitive high-performance liquid chromatographic method. There were no significant differences between colestipol treatment and control for peak plasma concentration (Cmax), time to peak concentration (Tmax), area under the plasma concentration-time curve (AUC), mean residence time (MRT), elimination rate constant (Kel), or elimination half-life (t1/2). Cholestyramine treatment resulted in a significant decrease in AUC (26%, p < 0.05) and Cmax (34.4%, p < 0.01) and a significant increase in Tmax (80%, p < 0.01) and MRT (20.2%, p < 0.05). Cholestyramine administration showed no significant effect on the Kel and t1/2 values. A significant correlation was obtained between the increase in MRT and the increase in Tmax. The confidence intervals (90%) of the mean values of the pharmacokinetic parameters (AUC0-infinity and Cmax) for the colestipol: control ratio were well within the acceptable range of 100 +/- 20, whereas those for the cholestyramine: control ratio were outside it. Colestipol treatment was found to be bioequivalent to the control treatment by Schuirmann's two one-sided t tests, while cholestyramine treatment was found to be bioinequivalent.(ABSTRACT TRUNCATED AT 250 WORDS)

Absorption↗

Correlation between nephrotoxicity and pharmacokinetic parameters of gentamicin.

Gentamicin pharmacokinetics were determined in 26 critically ill adult patients. All had normal or only moderately reduced renal function based on serum creatinine concentration and clearance. The average half-life of elimination was 4.68 h, creatinine clearance was 3.9 l/h, and gentamicin clearance was 2.86 l/h. There was a highly significant correlation between the area under the serum concentration-time curves (AUC) and the peak and trough concentrations (r = 0.908, 0.980, P < 0.05, respectively). Serum gentamicin concentrations rose rapidly in 10 patients who showed deterioration of kidney function after 5 days of therapy. Gentamicin peak concentrations increased by 31%, while trough concentration increased by 121%. The mean percentage change in half-life was 68.49%, while the mean percentage change in renal function was 44.38%. Linear regression analysis of AUC versus the percentage change in kidney function revealed a significant increase in AUC with decrease in kidney function (r = 0.909, P < 0.05). There was a significant increase in half-life with decrease in kidney function (r = 0.948, P < 0.05).

Adult↗

Effect of famotidine on ciprofloxacin pharmacokinetics after single intravenous and oral doses in rats.

The effect of intravenous (3.5 mg/kg) and oral (5 mg/kg) famotidine on ciprofloxacin pharmacokinetics after single (i.v.) intravenous (5 mg/kg) and oral (20 mg/kg) doses were examined in the rat. Famotidine co-administration significantly increased the terminal elimination half-life of ciprofloxacin (54% and 29% following i.v. and oral administration, respectively) and tended to reduce the total body clearance by 27% and 34% following i.v. and oral routes, respectively. The area under the plasma concentration-time curve and the mean residence time in the body after i.v. and oral doses were significantly increased following famotidine co-administration. No changes in the steady-state apparent volume of distribution was observed after i.v. administration. The maximum plasma concentration and the time to peak concentration after oral dosing were also unaffected. These results suggest a possible reduction in the total clearance of ciprofloxacin, owing to inhibition of its renal tubular excretion by famotidine. Further studies are warranted to determine whether this interaction occurs in humans.

Administration, Oral↗

The effect of colestipol and cholestyramine on the systemic clearance of intravenous ibuprofen in rabbits.

The effect of oral administration of the non-absorbable anion-exchange resins cholestyramine and colestipol on the systemic clearance and other pharmacokinetic parameters of intravenously administered ibuprofen (25 mg kg-1) was studied in rabbits. Single doses of colestipol hydrochloride (0.4 g kg-1) or cholestyramine (0.17 g kg-1) were given 30 min before ibuprofen administration. In cholestyramine-treated rabbits a significant reduction in ibuprofen plasma concentration was observed compared with both control (water only) and colestipol-treated rabbits. Cholestyramine treatment resulted in a significant decrease in the terminal elimination half-life and the mean residence time. Furthermore, a 31% increase in the systemic clearance and 23% decrease in the area under the plasma concentration-time curve were also observed in cholestyramine-treated rabbits. Colestipol treatment did not change these parameters. The volume of distribution parameters (Vdss and Vd(area)) did not change following either treatment. The changes in the pharmacokinetic parameters are compatible with an acceleration of ibuprofen elimination induced by oral administration of cholestyramine and not by colestipol. This effect is thought to be due to augmentation of net biliary excretion through enteric binding.

Administration, Oral↗

The effects of cholestyramine and colestipol on the absorption of diclofenac in man.

The effect of oral administration of the non-absorbable anion-exchange resins cholestyramine and colestipol hydrochloride on the absorption of diclofenac in man was studied. Adsorption studies in vitro were also performed. In a randomized crossover study consisting of three phases, single doses of water suspensions of colestipol hydrochloride (10 g), or cholestyramine (8 g), or water only were given to six healthy male volunteers immediately following ingestion of diclofenac (100 mg). After dosing, serial blood samples were collected for a period of 8 hours. Plasma harvested from blood was analyzed for diclofenac by a sensitive and accurate high-performance liquid chromatographic method. The area under the plasma concentration-time curve was moderately (33%, p < 0.05) reduced by colestipol, and greatly reduced (62%) by cholestyramine. The maximum plasma concentration was reduced (58%) by colestipol and even more (75%) by cholestyramine treatment. The in-vitro adsorption studies showed that colestipol has a weaker capacity for adsorption of diclofenac compared to cholestyramine. The in-vivo data suggest a reduction of diclofenac bioavailability when colestipol or cholestyramine is administered concomitantly.

Absorption↗

Effect of oral activated charcoal on propranolol pharmacokinetics following intravenous administration to rabbits.

The pharmacokinetics of propranolol following intravenous administration (1 mg/kg), with and without treatment with oral activated charcoal, was investigated in rabbits. In charcoal-treated rabbits a significant reduction in propranolol serum concentrations was observed compared to control animals. Charcoal treatment significantly reduced the half-life of elimination (16.6%) and the mean residence time (19%) of propranolol. A 17% increase in the systemic clearance and a 14% decrease in AUC were also noted. Charcoal administration did not significantly alter the volume of distribution (Vc' V(area) and Vss) or the apparent distribution half-life. A two-compartment model adequately described propranolol in control and treated rabbits. The results indicate that administration of oral activated charcoal enhances the systemic elimination of propranolol. This is presumably mediated by interruption of the enterohepatic circulation of propranolol by activated charcoal.

Administration, Oral↗

Effect of oral activated charcoal on vancomycin clearance in rabbits with acute renal failure.

The effect of oral administration of activated charcoal on total body clearance of vancomycin administered intravenously (7.5 mg/kg) has been studied in normal rabbits and rabbits with induced renal failure. Gastric intubation of a single dose (10 g) of activated charcoal to normal rabbits did not produce a statistically significant effect on any pharmacokinetic parameter for vancomycin. The mean vancomycin clearances were (mean +/- s.d.) 80.82 +/- 6.8 and 75.24 +/- 9.61 ml/h/kg with and without activated charcoal administration, respectively. To examine whether renal failure would influence the effect of activated charcoal and enhance the systemic clearance of vancomycin, uranyl nitrate was used (0.75 mg/kg, i.v.) to induce acute renal failure in rabbits. The derived pharmacokinetic parameters of vancomycin were consistent with renal failure. No significant differences were observed in any of the calculated pharmacokinetic parameters between the control and charcoal treated rabbits. The lack of effect may be attributed to the large molecular weight of vancomycin.

Acute Kidney Injury↗

A sensitive high-performance liquid chromatographic analysis of propranolol in serum.

A rapid and sensitive high-performance liquid chromatographic (HPLC) assay was developed for quantitative determination of propranolol in serum. The assay is performed after single extraction of propranolol and indenolol [internal standard (IS)] from alkalinized serum into ether and eluted from C-18 U Bondapak column with a mobile phase composed of methanol: 0.01 M phosphate buffer pH 3.4 (40:60%, v/v). The column eluant was monitored on a fluorescence detector. Measurement was achieved by taking the peak height ratio of propranolol and comparing it to that of the IS. The detection limit for propranolol in serum is 2.5 ng/ml. Intraday coefficients of variation (CV) ranged from 2.84 to 4.0% and interday (CVs) from 5.8 to 8.4% at three different concentrations. The relative and absolute recoveries varied from 93.8 to 102.3%. Preliminary stability tests showed that propranolol is stable for at least 3 weeks in serum after freezing. The method is applied for the determination of the pharmacokinetic parameters of propranolol after intravenous administration (1 mg/kg) to rabbits.

Animals↗

Comparison of non-kinetic and kinetic approaches to individualization of gentamicin dosage.

A prospective study was carried out in 40 acutely ill patients to compare the non-kinetic and kinetic approaches to individualization of the dosage regimen of gentamicin. The patients were divided into two equal groups. For the non-kinetic group, the doses were derived from the physician's personal experience, on a mg/kg basis, and by use of nomograms. The total daily dose ranged from 1.43 to 4.5 mg/kg. Based on serum concentration measurements, the dosage regimen for individual patient was calculated by Sawchuk-Zaske's method. The calculated doses were compared to the prescribed doses in each patient. Of the patients on empirically prescribed doses 65% received 36% more drug than the calculated dose and 20% received 36% less than the calculated dose. The calculated dosing intervals were greater than the recommended intervals in 60% of the patients. The gentamicin trough concentration was greater than 2 micrograms/ml in 70% of the patients. There was a significant tendency to overdosage of the patients. For the kinetic group, following administration of the calculated dose, the steady-state peak and trough concentrations in each patient were measured. The correlation of measured to predicted steady-state serum concentrations was excellent (r = 0.9968, p less than 0.05). About 85% of the served trough concentrations and 90% of the peak values fell within the therapeutic range. The mean of the prediction error (ME), mean absolute error (MAE), mean squared error (MSE), and root mean squared error (RMSE) of the trough and peak concentrations were calculated. The 95% confidence interval of the ME for the trough and peak concentrations included zero, which shows that the prediction was not significantly biased.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

High-performance liquid chromatographic analysis of indomethacin in serum.

A rapid high-performance liquid chromatographic (HPLC) method for quantitative determination of indomethacin in serum is described. The assay was performed after single extraction of indomethacin and itraconazole (internal standard) from serum using diethyl ether and eluted from a 4 micron C-18 reversed-phase column at ambient temperature. The mobile phase consisted of ethanol:water:glacial acetic acid (65:34:1, v/v) pumped isocratically at a flow rate of 1.3 ml/min. The effluent was monitored at 254 nm. Quantification was achieved by the measurement of the peak area ratio, and the absolute recoveries ranged from 94 to 97%. Within-day coefficients of variation (CV) ranged from 2.72 to 5.70% and between-day CV varied from 3.61 to 6.1%. Stability testing indicated that indomethacin is stable for at least 30 days in serum at -20 degrees C. The method was used to study indomethacin pharmacokinetics in rabbits.

Animals↗

The effect of oral activated charcoal on the systemic clearance of gentamicin in rabbits with acute renal failure.

The effect of oral administration of activated charcoal on total body clearance of gentamicin administered intravenously (2 mg kg-1) has been studied in normal rabbits and rabbits with induced renal failure. Gastric intubation of a single dose (10 g) of activated charcoal to normal rabbits produced a significant reduction in gentamicin serum concentrations compared to control. Significant differences between treated and control groups, compatible with enhancement of gentamicin elimination, were observed in the calculated pharmacokinetic parameters (Kel, t 1/2, CL and AUC). To examine whether renal failure could augment the effect of activated charcoal in enhancing the systemic clearance of gentamicin, uranyl nitrate was used (0.75 mg kg-1, i.v.) to induce acute renal failure in rabbits. The derived pharmacokinetic parameters of gentamicin during the control phase in these animals were consistent with severe renal failure. The administration of activated charcoal, 2.5 h following gentamicin injection, produced a steeper decline in gentamicin concentration-time profiles and significant changes in Kel, t 1/2 and CL. The Kel and CL values increased to about 200%, while the t 1/2 value decreased to about 50%. The apparent changes in the pharmacokinetic parameters induced by charcoal administration were more marked in rabbits with renal failure than in normal rabbits; however, induction of renal failure did not augment the charcoal-induced clearance of gentamicin quantitatively.

Acute Kidney Injury↗

Enhancement of morphine clearance following intravenous administration by oral activated charcoal in rabbits.

A single dose of activated charcoal (10 g) significantly reduced the half-life of elimination (1.02 +/- 0.10 and 0.70 +/- 0.04 h for the control and treated groups, respectively) and mean residence time (1.01 +/- 0.12 and 0.76 +/- 0.05 h for the control and treated groups, respectively) of morphine in rabbits. A 40% increase in the systemic clearance (85.73 +/- 7.72 and 122.64 +/- 16.32 mL min-1 kg-1 for the control and treated groups, respectively) and a 30% decrease in AUC (204.38 +/- 22.20 and 140.03 +/- 19.32 micrograms h L-1 in the control and treated groups, respectively) were also noted. Charcoal administration did not significantly alter the volume of distribution (Varea and Vss) or the apparent distribution half-life. A two-compartment model adequately described morphine kinetics in control and treated rabbits; charcoal administration produced a significant increase in the tissue compartment rate constant (K21). This finding indicates that activated charcoal not only enhances the systemic elimination of morphine, but also accelerates the rate of transfer of morphine from the tissue compartment to the central compartment.

Administration, Oral↗

Stability-indicating high-performance liquid chromatographic assay for the determination of metoclopramide hydrochloride in pharmaceutical dosage forms.

A simple, reliable and selective high-performance liquid chromatographic method for the determination of metoclopramide hydrochloride in pharmaceutical dosage forms has been developed and evaluated. The drug and the internal standard (phenobarbitone) were eluted from a 5-micron C8 reversed-phase column at ambient temperature with a mobile phase consisting of phosphate buffer (10 mM)-methanol-acetonitrile (50 + 28 + 22) adjusted to pH 4.8 with orthophosphoric acid. The mobile phase was pumped at a flow-rate of 1.5 ml min-1 and the effluent was monitored spectrophotometrically at 214 nm. The retention times of the internal standard and metoclopramide hydrochloride were 3.0 and 7.5 min, respectively. Quantification was achieved by measuring the peak-height ratio of the drug to the internal standard. A linear relationship was found over the range 1-10 micrograms ml-1. Within-day coefficients of variation (CVs) ranged from 0.50 to 1.70% and between-day CVs from 0.68 to 4.07% at three different concentrations. The developed procedure was compared with the current BP method for the assay of metoclopramide hydrochloride in tablets. The proposed method was also used to study the stability of metoclopramide hydrochloride.

Chemical Phenomena↗

High-performance liquid chromatographic analysis of theophylline in serum and its use in therapeutic drug monitoring.

A rapid, highly sensitive high-performance liquid chromatographic method has been developed for the determination of theophylline in serum using beta-hydroxyethyltheophylline as an internal standard (IS). Theophylline and IS were extracted from serum using a mixture of dichloromethane: isopropanol (90: 10, v/v) and eluted from a 5 microns, C-18 reversed-phase column at 60 degrees C with a mobile phase consisting of sodium acetate buffer-acetonitrile (90:10, v/v), at a flow rate of 1 ml/min with ultraviolet detection at 280 nm. Each analysis required no longer than 7 min to perform. Quantification was achieved by the measurement of the peak: height ratio and the relative and absolute recoveries varied from 86 to 100%. Within-day coefficients of variation ranged from 2.9 to 5.1% and between-day coefficients of variation from 1.1 to 5.9% in subtherapeutic, therapeutic, and toxic concentrations.

Chromatography, High Pressure Liquid↗

Bioequivalency of ranitidine tablets.

The bioavailability of two brands of ranitidine tablets was studied in 10 healthy volunteers. Formulation factors were compared by performing disintegration, dissolution and content uniformity tests. Plasma concentrations of ranitidine were measured using a sensitive and precise high pressure liquid chromatographic (HPLC) procedure. Pharmacokinetic parameters were determined for both formulations and included: Cmax, AUCt, AUC infinity, tmax, t1/2 and the terminal rate of elimination (k). Statistical analysis revealed that differences between the brands were not significant. The two formulations can be considered to be bioequivalent.

Adult↗